Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine vs Epirubicin Immediate Instillation in Bladder Cancer
NCT04947059Phase 3Recruiting
- Sponsor
- University of Thessaly
- Start
- Dec 2021
- Primary completion
- Oct 2025
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in bladder cancer comparing Gemcitabine with Epirubicin (2 arms). Primary endpoints: Bladder cancer recurrence at 12 months and Bladder cancer progression at 12 months. Started Dec 2021; status: recruiting.
02
Drugs
gemcitabineepirubicin
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT04947059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04947059.